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The glucocorticoid receptor (GR) is a major drug target in inflammatory disease. However,
chronic glucocorticoid (GC) treatment leads to disordered energy metabolism, including
increased weight gain, adiposity, and hepatosteatosis — all programs modulated by the
circadian clock. We demonstrated that while antiinflammatory GC actions were maintained
irrespective of dosing time, the liver was significantly more GC sensitive during the day.
Temporal segregation of GC action was underpinned by a physical interaction of GR with
the circadian transcription factor REVERBa and co-binding with liver-specific hepatocyte
nuclear transcription factors (HNFs) on chromatin. REVERBa promoted efficient GR
recruitment to chromatin during the day, acting in part by maintaining histone acetylation,
with REVERBa-dependent GC responses providing segregation of carbohydrate and lipid
metabolism. Importantly, deletion of Reverba inverted circadian liver GC sensitivity and
protected mice from hepatosteatosis induced by chronic GC administration. Our results
reveal a mechanism by which the circadian clock acts through REVERBa in liver on
elements bound by HNF4A/HNF6 to direct GR action on energy metabolism.
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Introduction
Glucocorticoids (GCs; cortisol in humans, corticosterone in 
rodents) are critical regulators of energy metabolism and immuni-
ty. Their secretion by the adrenal gland follows a circadian pattern, 
with serum concentrations peaking before the active phase (day in 
humans, night in rodents). Synthetic GCs are the most potent anti-
inflammatory agents known and are widely used therapeutically, 
with more than 1% of the population in the United Kingdom hold-
ing a prescription long-term. However, frequent therapeutic use 
is accompanied by development of severe side effects, notably fat 
accumulation, hyperglycemia, and hepatosteatosis (1). Inactive GC 
receptor (GR) is bound by ligand in the cytoplasm and undergoes 
translocation to the nucleus, where it binds GC response elements 
(GREs) in the genome to either enhance or repress gene transcrip-
tion. Mechanisms to explain how the same molecule can drive 
gene activation or repression remain under investigation, but likely 
require an allosteric change induced by DNA target sequence and/
or co-binding with other transcription factors. For gene activation, 
homodimeric GR recruits coactivator molecules including steroid 
receptor coactivators (SRC1–3) and histone acetyltransferases 
(CBP/p300) (2, 3). In contrast, gene repression involves tethering 
of GR to transcription factors such as the inflammatory regulator 
NF-κB and in doing so interferes with that factor’s transactivation 
mechanism (4–6), or direct binding to negative GREs to recruit 
repressing cofactors (7, 8).
The subject of cell type–specific GR action is attracting increas-
ing attention, and the existence of “primed” enhancer sites direct-
ed by tissue-specific transcription factor activity has emerged as 
an important determinant of GC effects (9, 10). This work has 
identified transcription factors that can serve as pioneer factors 
for GR, such as AP-1, which drives a state-dependent change in 
the GR cistrome in activated macrophages (11), and the hepato-
cyte-specific transcription factors HNF4A and HNF6, which do 
the same in liver (12). In this way GR and other nuclear receptors 
have preprogrammed cistromic profiles in target cells that await 
appropriate environmental cues, such as hormone signals.
Circadian rhythms in mammals are built and governed by a 
complex hierarchy of molecular and cellular interactions. Histor-
ically, the central hypothalamic suprachiasmatic nucleus (SCN) 
pacemaker has been viewed as pivotal to systemic synchrony, but 
recent studies now clearly demonstrate that peripheral organs 
can maintain tight local synchrony divergent from the SCN in 
response to feeding and metabolic cues, and a range of environ-
mental signals (13–15). At the molecular level, the circadian clock 
is conserved in all cell types and is driven by a rhythmic feed-for-
ward transcriptional/translational loop (BMAL1, CLOCK/
NPAS2) and rhythmic negative feedback (Cry1/2, Per1/2, and 
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fore timed to the middle of the day (zeitgeber time 6 [ZT6], 1:00 
pm) or the middle of the night (ZT18, 1:00 am), when endoge-
nous corticosterone concentrations are similar (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI96138DS1). We also analyzed 
expression and localization of GR in the lung and liver, and we 
did not observe substantial changes in GR expression or nucle-
ar localization between these time points (Figure 1A; and Sup-
plemental Figure 1, B and C, P = NS). Recent data have shown a 
change in GR phosphorylation and translocation to the nucleus 
by time of day, but critically, this change accompanies the diur-
nal change in serum corticosterone and likely reflects the activa-
tion of GR by binding to its endogenous ligand. It is noteworthy 
that our studies were performed at the time points when serum 
corticosterone, GR phosphorylation at S275 and S212, and nucle-
ar GR abundance are similar in mouse liver (26, 27). We har-
vested total RNA from lung and liver of vehicle- and dex-treated 
mice at ZT6 and ZT18 (Figure 1B). RNA was analyzed by RNA 
sequencing (RNA-Seq), and across tissues and time points 2,419 
GC-regulated genes were identified. Of these, the majority were 
tissue specific (627 genes in lung, 1,665 genes in liver). There 
was a restricted set of common targets (127 genes), and these 
were associated with antiinflammatory GC effects.
In lung, a similar total number of genes were responsive to 
GC at the 2 administration times, but of these, only 43% were 
responsive to dex at both time points, indicating a temporal 
remodeling of the GC response (Figure 2A). Gene ontology anal-
yses revealed antiinflammatory pathways as highly GC regulated 
at both times (Supplemental Tables 1 and 2), with transactivated 
and transrepressed genes equally represented (Figure 2B). RNA-
Seq tracks were compared with GR ChIP sequencing (ChIP-Seq) 
tracks from ZT4 to confirm direct GR targets, and time-of-day 
effects were confirmed by quantitative real-time PCR (qRT-
PCR) for Efna1, a night-specific GC target, and Wt1, a day-spe-
cific GC target (Figure 2, C and D).
Timing of administration had a major effect on GC sensitivity 
in the liver, with 1,709 genes responsive to daytime GC admin-
istration and only 211 genes regulated at night (Figure 2E). As in 
lung, similar proportions of transactivated and transrepressed 
genes were observed at both times. Again, the RNA-Seq tracks 
were compared with GR ChIP-Seq tracks at ZT4, and the time- 
dependent switch in GC sensitivity was validated by qRT-PCR for 
Dio1 and Aldh1b1 (Figure 2, F and G).
Our data analysis revealed an excess of daytime GC-regulated 
genes in the liver. KEGG pathway analyses revealed a strong time 
of day–dependent regulation of energy metabolism, including 
carbohydrate, lipid, pyruvate, and oxidative phosphorylation (Sup-
plemental Figures 2 and 3, Supplemental Tables 3 and 4). These 
analyses highlighted a GC-dependent impact on mitochondrial 
function in a time of day–specific manner. We therefore analyzed 
mitochondrial mass and bioenergetic metabolite concentrations 
in livers from GC-treated mice by day and by night. A profound 
GC-induced loss of mitochondrial mass was observed in liver, 
but only in animals treated in daytime (Supplemental Figure 3B), 
when AMP levels rise in response to the fasted state. A change in 
mitochondrial mass did not occur in lung (Supplemental Figure 
3C). The AMP concentration showed a small but significant incre-
the nuclear receptors REVERBa and REVERBb). REVERBa and 
REVERBb constitute a negative feedback loop to stabilize core 
clock oscillation. In the liver, REVERBs have a major role in 
conferring clock control to lipogenic gene expression (15), and 
recent discoveries identify both DNA binding regulation of the 
core clock and DNA binding–independent regulation of energy 
metabolism as distinct mechanisms of action. The latter requires 
HNF6/HNF4A factors to tether REVERBa to the genome (16, 
17). We now know that the circadian clock is a potent regulator 
of both metabolism and immunity (18–21). Disruption of clock 
genes (Bmal1, Clock, Cry, Reverb) has been shown to profoundly 
alter energy metabolism and dysregulate inflammatory respons-
es — all of which are also affected by GR. Close coupling between 
cellular clock machinery and GR is supported by protein interac-
tions between CRY and GR to affect carbohydrate metabolism, 
and by the potent clock-entraining activity of the GR, which 
transactivates Per2 (22). An intriguing recent report also suggest-
ed functional crosstalk between the GR and REVERBa, although 
the mechanism and physiological consequences of such an inter-
action were not delineated (23). Furthermore, studies in the 
rat suggest that timing of exogenous GC dosing impacts liver 
lipid metabolism, but again the underlying mechanism was not 
determined (24). These timing-dependent phenomena are inter-
esting, especially because the CRY:GR crosstalk mechanism 
primarily affected carbohydrate metabolism, suggesting the 
existence of multiple points of circadian clock:GR coregulation. 
Despite this, there has been limited application of timing infor-
mation in GC therapy, with nighttime release of prednisolone 
offering additional therapeutic effect (25). As so little is known 
about how biological time affects GR function, we investigated 
circadian control of GC action.
We reveal a major time-of-day gating in the spectrum of 
GC-regulated genes when mice are treated in the day or night. 
This temporal dynamic is especially pronounced in metabolic 
(liver) versus nonmetabolic (lung) tissues, and segregates carbo-
hydrate and lipid metabolic processes. Deletion of Reverba caused 
a profound shift in both the makeup and time dependency of 
GC-regulated gene expression. Focusing on the liver, we identi-
fy a high prevalence of closely related genomic binding sites for 
GR and REVERB transcription factors, as well as direct physical 
interaction of GR with REVERBa. Importantly, chronic GC dosing 
in mice drove a shift in liver lipid metabolism, with only a minor 
impact on carbohydrate metabolism. The sparing of Reverba-KO 
(REVERBaKO) mice from GC-induced hepatosteatosis marks the 
physiological importance of the GR-REVERB interaction. These 
findings are significant for the development of chronotherapy 
using GC, as for example the recently launched Lodotra modified 
release prednisolone preparation (25), which delivers active GC to 
patients at night (equivalent to the mouse day).
Results
Time of day determines GC action. We first defined the time 
dependency of acute GC responses using the synthetic GC dexa-
methasone (dex; 1 mg/kg) in nonmetabolic (lung) and metabolic 
(liver) tissue. Secretion of endogenous GC follows a circadian 
pattern, with peak serum concentrations occurring before the 
active phase (night in rodents). Dex administration was there-
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GC response, and to identify additional circadian crosstalk with 
GR, we determined the proximity of the mapped cistrome of GR, 
obtained at ZT4, to each of the circadian transcription factors in 
liver (Figure 3A). Putative co-binding was defined as a distance 
of less than 120 bp between ChIP-Seq summits and high-strin-
gency (fold enrichment 30 [FE30] for GR data) co-bound sites, 
indicating a degree of cooperative binding (co-binding delineat-
ed in the leftmost peak in Figure 3A). Pooled data from across 
the circadian cycle were used in order to avoid potential com-
plications arising from the different phases of core circadian 
transcription factor expression in mouse liver (28). The level of 
co-binding was quantified by determining the ratio of co-bind-
ing events (interpeak distance <120 bp) to non-proximal bind-
ing events (interpeak distance >120 bp). As it compares the 
relative abundance of proximal and non-proximal binding, the 
approach is not sensitive to differences in the total number of 
transcription factor binding peaks seen between analyzed cis-
tromes (Supplemental Figure 4, C–F).
ment in response to GC in the day, but no response at night, when 
the mice are in an energetically replete state and AMP concentra-
tions are low (Supplemental Figure 3, D and E). There was also a 
sharp fall in the NAD+/NADH ratio in response to GC treatment 
in the day and no change observed at night (Supplemental Figure 
3F). No differences in ATP or ADP concentrations were seen by 
time of day or treatment status (Supplemental Figure 3D), indicat-
ing that the altered mitochondrial mass is compensated by greater 
ATP synthesis efficiency.
Identification of REVERB, and CRY co-binding with GR in the 
hepatic genome. The time-dependent switch in GC sensitivity in 
liver suggests the operation of a circadian control mechanism 
capable of targeting the GR. The chromatin loading of these core 
clock transcription factors shows strong daily variation (based 
on data reported in ref. 28, Supplemental Figure 4, A and B), and 
there is evidence that the CRY proteins bind GR to direct GR 
control of carbohydrate metabolism in the liver (29). To inves-
tigate the role of CRY in conferring the time-of-day variation in 
Figure 1. GCs induce tissue-specific transcriptomes. (A) GR immunohistochemistry in lung and liver at ZT8 (Day) and ZT20 (Night). GR expression is 
shown in brown; nuclei are blue. Br, bronchioles. C57BL/6 mice were given vehicle or 1 mg/kg i.p. dex at ZT6 (1 pm, day) or ZT18 (1 am, night) and culled 
2 hours later, and lung and liver were analyzed by RNA-Seq. (B) Venn diagram depicting all GC-regulated genes identified byDESeq2 (n = 2 per group, 
>2-fold change to vehicle control, <0.05 FDR). Lung- and liver-specific targets are indicated, with gene ontology terms for each group listed below. SRP, 
signal recognition particle.
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erated by different antibodies and showed a high degree of over-
lap (Supplemental Figure 4E), as would be expected, as the DNA 
binding specificities of the two transcription factor paralogs show 
near identity (16). Other core clock transcription factors (BMAL1, 
CLOCK, PER1/2), however, showed little co-binding with GR.
To investigate the contribution of time-of-day variation in 
circadian transcription factor expression and function to our 
co-binding analysis, we separated the CRY1 and CRY2 cis-
Co-binding of GR and CRY was revealed, consistent with the 
previously reported physical interaction between GR and CRY (29), 
and this observation provided useful confirmation that our analyt-
ical approach was capable of detecting a previously determined 
co-binding event. In addition, we discovered a surprisingly high 
frequency of co-binding of GR with REVERBa and REVERBb, with 
median interpeak distances of only 93 and 80 bp, respectively (Fig-
ure 3A). Notably, the REVERBa and REVERBb cistromes were gen-
Figure 2. GC sensitivity in liver is regulated by time of day. (A) Histogram depicting number and time-of-day regulation of GC targets for each tissue.  
(B) Base mean expression versus log2 fold change plots for GC-regulated genes in lung show direction of regulation. (C and D) Two time-specific exemplars 
were validated by qRT-PCR (Veh and dex), and GR DNA binding (GR) was assessed via analysis of GR ChIP-Seq data. (E) Base mean expression versus log2 
fold change plots for GC-regulated genes in liver show direction of regulation. (F and G) Two time-specific exemplars were validated by qRT-PCR, and GR 
DNA binding was assessed using GR ChIP-Seq data. For qRT-PCR data, individual data points are shown with median (n = 4 per group). Statistical analysis 
by Kruskal-Wallis test with a Dunn’s multiple comparisons correction, where *P < 0.05, **P < 0.01. Volcano plots depict all GC-regulated genes identified 
byDESeq2 (n = 2 per group, >2-fold change to vehicle control, <0.05 FDR).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 4 5 8 jci.org   Volume 128   Number 10   October 2018
ar receptors (Figure 3B and Supplemental Figure 10). Interestingly, 
we did not see a ligand dependence in the interaction between the 
two nuclear receptors, implying that the GR interaction surface is 
not the ligand-binding domain. We went on to investigate coim-
munoprecipitation of endogenous proteins in the liver. We selected 
the time point of maximal endogenous REVERBa protein expres-
sion but were unable to confidently identify an interaction. This 
may reflect the low expression level of the two endogenous nucle-
ar receptors and the dynamic interactions that occur on chromatin 
(Supplemental Figure 11).
REVERBa expression is required to maintain appropriate time-
of-day GR action in the liver. The discovery that GR and REVERBa 
can exist within the same molecular complex implies an important 
functional crosstalk between the two receptors. To investigate this 
possibility, we examined GC responses in mice lacking Reverba 
tromes by time, and analyzed GR-CRY co-binding with GR cis-
tromes generated at 6:00 am and 6:00 pm. (Supplemental Fig-
ure 4, F and H). The co-binding of GR and CRY was seen at all 
the time points analyzed and followed the pattern of DNA load-
ing of the CRYs. Similarly, analysis of REVERBa and REVERBb 
cistromes with GR binding at 6:00 a.m. or 6:00 p.m. confirmed 
our findings of a high incidence of co-binding with GR (Supple-
mental Figure 4G).
The observation, made using computational approaches, that 
REVERBs and GR bind in close proximity to selected sites in the 
genome suggests that the two transcription factors interact. To 
investigate this possibility, we set out to use a different approach 
to test REVERBa interaction with GR, via coimmunoprecipitation. 
Using expression of tagged GR and REVERBa in HEK cells, we 
observed a strong and specific interaction between the two nucle-
Figure 3. REVERBa regulates GR function. (A) Co-binding histograms depict the distance between GR binding events and the nearest clock transcription 
factor ChIP-Seq summit, using 3 stringencies (FE scores). Median interpeak distances for the highest stringency (FE30) is shown. (B) Coimmunoprecip-
itation of epitope-tagged REVERBa and GR. C57BL/6 (WT) and REVERBaKO mice were given 1 mg/kg i.p. dex at ZT6 (day) or ZT18 (night) and culled 2 
hours later, and livers were analyzed by RNA-Seq. (C) Venn diagram depicts all GC-regulated genes identified byDESeq2 (n = 5 per group, >2-fold change to 
vehicle control, <0.1 FDR). pHT, polyhistidine tag.
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Figure 4. REVERBa does not regulate antiinflammatory GC effects. (A) Gene ontology (Enrichr) grids for REVERBa-independent GC targets with the 2 
highest-ranking terms listed underneath. (B) Graphs show RNA-Seq reads for antiinflammatory GC target genes from liver RNA-Seq. Individual samples 
(n = 5) are plotted with the median for each group. Bone marrow–derived macrophages were isolated from REVERBaKO and WT littermate control mice, 
treated with vehicle or 100 nM dex for 1 hour, then with 100 ng/ml LPS for 4 hours. (C) GC regulation was determined by qRT-PCR for Dusp1 and Il6; no 
genotypic differences were observed; data shown as median. Two-way ANOVA (macrophages, n = 3) effect of treatment, P < 0.001; Fisher’s exact test 
adapted for negative binomial distribution (RNA-Seq), *q < 0.05, **q < 0.01, ****q < 0.0001. RQ, relative quantity.
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and littermate controls. The loss of REVERBa caused a dramatic 
change in the temporal characteristics of GC response, with loss 
of many daytime-responsive genes, and acquisition of additional 
GC targets at night (Figure 3C).
Gene ontology analysis using Enrichr highlighted that genes 
consistently responsive to GC signaling (irrespective of time of 
day or of REVERBa deletion) were highly enriched for the anti-
inflammatory actions of GR (Figure 4A). We therefore examined 
the actions of GR on index inflammatory target genes in the liver 
and isolated immune populations of REVERBaKO and WT mice 
(Figure 4B). We demonstrate that induction of antiinflammatory 
effectors Gilz and Dusp1, and repression of the proinflammatory 
effectors Il1b and Ccl2 by GC is not under REVERBa control. We 
extended our analysis to isolated bone marrow–derived macro-
phages activated in vitro with LPS (Figure 4C) and further show 
that loss REVERBa had no effect on the potent antiinflammatory 
actions of GR stimulation.
Analysis of gene regulation by GC in WT mice showed a dramatic 
loss in the responsiveness of genes involved in carbohydrate and lipid 
metabolism at night (Supplemental Figure 2). Again, REVERBaKO 
animals were used to assess the impact of REVERBa on the time-of-
day segregation of GC action. We first identified daytime GC-regulat-
ed target genes in both genotypes and further enriched this gene set 
by identifying genes close to GR/REVERBa co-bound peaks (derived 
from analysis presented in Figure 3A). In WT mice, 223 genes were 
identified close to GR/REVERBa co-bound sites, which were exclu-
sively GC responsive in the day. A set of 64 such genes were identified 
only in REVERBaKO animals (Figure 5A). Gene ontology analysis of 
the combined set of genes that either lose or gain GC response by day 
identified carbohydrate metabolic processes as being highly enriched 
(Figure 5B). Therefore, we propose that the loss of GC gene regula-
tion observed in the liver of REVERBaKO mice during the day will 
result in altered carbohydrate metabolic responses to GC, by affect-
ing the pathways identified and mapped in Supplemental Figure 2.
Figure 5. REVERBa selectively regulates GC action depending on time of day. (A) Daytime-regulated GC targets were further stratified for regions of 
GR-REVERBa co-binding from Figure 3. (B) Gene ontology (Enrichr) of GC-regulated, co-bound, REVERBa-dependent genes in the day. (C) Nighttime-reg-
ulated GC targets were further stratified for regions of GR-REVERBa co-binding from Figure 3. (D) Gene ontology (Enrichr) of GC-regulated, co-bound, 
REVERBa-dependent genes at night. (E) Dex suppression test via measurement of serum corticosterone at both ZT6 and ZT18 in WT and REVERBaKO 
mice with a single dose of dex 1 mg/kg. C57BL/6 (WT) and REVERBaKO mice were given 1 mg/kg i.p. dex or vehicle at ZT6 every 48 hours for 8 weeks. (F) 
C57BL/6 (WT) and REVERBaKO mice were given 1 mg/kg i.p. dex or vehicle at ZT6 every 48 hours for 8 weeks. Thymus weight was measured. Corticoste-
rone measurement, n = 5–12; thymus weight, n = 7–8, *P < 0.05, **P < 0.01, Mann-Whitney U test; shown as median.
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Figure 6. The effect of REVERBa on GC action is independent of cryptochromes. (A) C57BL/6 (WT) and REVERBaKO mice were given 1 mg/kg i.p. dex or 
vehicle at ZT6 every 48 hours for 8 weeks. Mice were assessed for effects on carbohydrate metabolism by fasting glucose (left), serum insulin (center), and 
liver glycogen content (right). (B) Mice were fasted for 4 hours and assessed for insulin tolerance (left) or fasted overnight for glucose tolerance (right)  
(n = 7–8). (C) Graphs show RNA-Seq reads for Gr (left), Cry1 (center), and Cry2 (right) target genes. (D) Graphs show RNA-Seq reads for known CRY1-regu-
lated genes. Individual samples from RNA-Seq (n = 5) are all plotted with the median for each group. Individual values and median are shown for serum 
glucose, serum insulin, and liver glycogen. Mean values are shown for GTT and ITT. *q < 0.05, **q < 0.01, ****q < 0.0001, Fischer’s exact test adapted for 
negative binomial distribution (RNA-Seq). *P < 0.05, **P < 0.01, 2-way ANOVA (fasting glucose, GTT, serum insulin, liver glycogen, and ITT).
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ing the fraction of small adipocytes and increasing the fraction of 
large adipocytes. This was seen to a lesser extent in the REVER-
BaKO mice (Figure 7, C and D, and Supplemental Figure 8), and 
analysis via 3-way ANOVA highlighted a significant interaction 
among treatment, genotype, and cell size (P < 0.0001). The cata-
bolic actions of GC, with accumulation of adipose tissue, are char-
acteristic of the changes seen in people treated with GC, and these 
changes impose a major limitation on therapeutic use of synthetic 
GC. It was intriguing that loss of REVERBa appeared to protect 
mice from this effect. Moreover, GC actions in the liver inhibit 
β-oxidation of fatty acids and ketogenesis, and promote synthesis 
of triglycerides, resulting in hepatosteatosis. Reverba deletion pro-
tected from GC-induced hepatic triglyceride accumulation, the 
most reliable quantitative measure of hepatosteatosis (Figure 7, E 
and F), with no effect on serum free fatty acids or triglycerides (Fig-
ure 7, G and H, and Supplemental Figure 9), suggesting that hepatic 
lipogenesis induced by GC is interrupted by loss of REVERBa.
Emergence of HNF and epigenetic factors as important mediators 
of GR/REVERBa crosstalk in the liver. In our studies, loss of Rever-
ba resulted in 73% of GC-regulated genes being transactivated, in 
contrast to 54% in WT animals (Figure 8A). Motif analysis at sites 
of hepatic GR/REVERBa co-binding revealed enrichment for the 
hepatocyte-specific transcription factors HNF6 and HNF4A in 
motif analysis of all GR sites (Figure 8B and Supplemental Fig-
ures 5 and 6). There was a high degree of overlap between the 
ChIP-Seq–identified binding sites of the 3 relevant transcription 
factors, HNF4A, GR, and REVERBa, close to those GC target 
genes that were dependent on REVERBa. This was seen both for 
day and night-time GC-regulated genes (Figure 8C). For exam-
ple, GC-regulated carbohydrate (Irs1, Gck) and fatty acid (Dgat2, 
Lpin2) metabolic genes show striking alignment of GR, REVERBa, 
and HNF4A binding (Supplemental Figure 7). Consistent with our 
findings, REVERBa was recently shown to be capable of binding 
DNA by tethering to HNF6 in a mechanism that does not require 
the REVERBa DNA binding domain (17), and HNF4A has previ-
ously been suggested as a GR pioneer factor in liver (22). REVER-
Ba repressive action involves recruitment of NCOR and HDAC3 
(17, 30), and indeed, many co-bound enhancers show time-of-
day changes in histone H3K9Ac (Supplemental Figure 7), a mark 
regulated by HDAC3. These changes in histone modification are 
therefore predicted to be the result of productive engagement by 
the REVERBa repressive complex. Thus, our data support a mech-
anism of GR action that requires the HNF4A transcription factor, 
and time-of-day variation in chromatin accessibility.
To test directly the proposal that reduced GC transactiva-
tion by night, and in response to loss of REVERBa, resulted from 
impaired recruitment of GR and altered chromatin remodeling, we 
first examined GR binding at well-characterized enhancers related 
to the gluconeogenic gene Tat and the lipogenic gene Lpin1 (Figure 
8D). The nighttime loss of GR recruitment in WT mice was indeed 
also seen by day in the REVERBaKO mice, suggesting a shared 
mechanism of action and implicating REVERBa in the time-of-day 
change in GR function. We next performed ChIP-Seq analysis in 
WT and REVERBaKO mice for histone H3K27Ac, a robust marker 
for transcriptionally permissive and active chromatin (31) (Figure 
8E). We examined genes regulated by GC by day and by night, 
using an approach similar to that previous applied to investigate 
We next examined nighttime-specific GC-dependent gene 
regulation. GC treatment of WT mice at night only regulated 66 
genes with putative co-binding targets; however, the REVERBaKO 
mice acquired 303 new GC gene targets (Figure 5C). Gene ontolo-
gy analysis of this combined set of lost and gained genes by geno-
type revealed strong enrichment of lipid metabolic genes (Figure 
5D). Therefore, the gain of nighttime GC-regulated genes in the 
REVERBaKO mice is predicted to result in an impact on GC regu-
lation of hepatic lipid metabolism.
REVERBa preferentially couples GR to the hepatic lipid metab-
olism program. In previous work, functional interactions between 
CRY and GR were identified (29). In CRY1/2 double-KO mice there 
was a striking loss of GC suppression of the hypothalamic- pituitary-
adrenal axis, with persistent high circulating corticosterone levels 
observed in some animals after an injection with the potent synthet-
ic GC dex. We did not see any differences in corticosterone suppres-
sion by time of day or Reverba genotype (Figure 5E).
Long-term GC treatment drives abnormal carbohydrate and 
lipid metabolism, and we therefore investigated the impact of GR/
REVERBa crosstalk on the metabolic consequences of chronic GC 
treatment. WT and REVERBaKO littermates were treated with 
dex, 1 mg/kg by i.p. injection, at ZT6 every 48 hours for 8 weeks 
(29). There was marked thymic atrophy to a similar degree in 
both genotypes (Figure 5F), further supporting a lack of crosstalk 
between GR and REVERBa in immune regulation.
To investigate the impact of REVERBa on chronic GC reg-
ulation of carbohydrate metabolism, we first measured fasting 
glucose concentration after 8 weeks of alternate-day dosing with 
1 mg/kg dex (29) (Figure 6A). Chronic GC led to a significant 
increase in circulating glucose only in WT animals. In contrast, the 
previously reported increase in insulin sensitivity characteristic of 
the REVERBaKO mice was lost in response to chronic GC treat-
ment (Figure 6B), but there were no effects on glucose tolerance 
or liver glycogen content (Figure 6, A and B).
Previous work has shown that loss of CRY1 and CRY2 results 
in a gain of GR transactivation; we therefore measured the 2 CRY 
genes. In the REVERBaKO mice, daytime Cry1 expression was 
higher than that in the WT mice, and there was no difference in 
nighttime Cry1 expression between genotypes (Figure 6C). The 
increase in GC response seen at night in the REVERBaKO ani-
mals was therefore not attributable to CRY1, or CRY2. The subtle 
impact of REVERBa loss on GC regulation of carbohydrate metab-
olism is in contrast to the major changes reported to follow from 
Cry1/2 double KO, where there was an amplification of the GC 
effect on gluconeogenesis (29). Therefore, the GC action pheno-
types differed considerably between Cry1/2 and Reverba. In our 
REVERBaKO mice, Gsk3a, Gsk3b, and the gluconeogenic genes 
Pck1 and Tat all showed increased induction to GC at night, the 
time at which Cry1 expression is high, again suggesting a Cry- 
independent mechanism of action (Figure 6D).
Chronic, low-dose GC treatment did not affect mouse body 
weight (Figure 7A). However, analysis of body composition by 
EchoMRI revealed a significant increase in body fat proportion in 
the GC-treated WT mice (Figure 7B). The REVERBaKO animals, 
in contrast, showed no significant change in fat mass in response to 
GC (Figure 7B). In agreement with this finding, dex treatment also 
increased adipocyte size and heterogeneity in WT mice, decreas-
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Figure 7. REVERBa regulates lipid metabolism. C57BL/6 (WT) and REVERBaKO mice were given 1 mg/kg i.p. dex or vehicle at ZT6 every 48 hours for 8 weeks. 
Mice were assessed for effects on lipid metabolism. Body weight (A) and body fat percentage by EchoMRI (B) were measured at the start and end of the study 
(n = 7–8). Visceral fat adipocyte size was assessed by H&E (C) and quantified (D) (x axis values, U/μm2; n = 5, average of 3 fields); original magnification, ×10. 
(E) H&E of liver, collected at cull; original magnification, ×10. Liver triglycerides (F), serum triglycerides (TG) (G), and free fatty acids (FFA) (H) were also ana-
lyzed (n = 8 liver, n = 7–8 serum). Graphs show data for individual animals with median; adipocyte area shows individual values and mean. Statistical analysis 
via 2-way ANOVA repeated measures (body weight and fat mass), 2-way ANOVA and 3-way ANOVA (adipocyte size), or Kruskal-Wallis test with a Dunn’s 
multiple comparison correction (hepatic triglycerides, serum triglycerides, and serum free fatty acids), *P < 0.05, **P < 0.01, ****P < 0.0001.
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suggest that a circadian, REVERBa-dependent mechanism exists 
that regulates GC regulation of hepatic lipid metabolism.
Our initial work simply tested the effect of timed administra-
tion of GC to intact WT mice. We observed clear organ-specific and 
time of day–specific differences in GC target gene expression. As 
previous work had elegantly shown a physical interaction between 
cryptochromes and the GR, with a functional effect on GC action 
in the liver, we studied the interaction between GR and various 
circadian clock proteins, including cryptochromes. In addition to 
cryptochromes, we also saw surprising co-binding between GR 
and the two REVERBs and confirmed this using coimmunoprecip-
itation, revealing REVERBa as a promising candidate mediating 
clock control of the GR, above and beyond the effects mediated by 
the cryptochromes.
To investigate the role of REVERBa, we repeated the acute GC 
dosing schedule in global REVERBaKO mice. There was a strik-
ing change, now with more genes regulated at night than in the 
day. Previous work identified a further potential point of crosstalk 
between GR and REVERBa, in that both nuclear receptors bind to 
the heat shock protein complex in the cytoplasm, and they exert 
reciprocal effects on nuclear localization (23). However, in our in 
vivo studies, we did not see a change in terms of number of target 
genes or amplitude of response, but rather a difference in the spec-
trum of target genes engaged by GR by time of day, and dependent 
on REVERBa.
The discovery that loss of REVERBa had such a major impact 
on GC regulation of both carbohydrate and lipid metabolic genes 
prompted us to examine the physiological impact in a chronic 
dosing study. In this protocol we used a low-dose dex administra-
tion schedule previously shown to reveal major changes in effect 
in the Cry1/2 double-KO mice. The study was timed to ensure a 
duration of exogenous GC dosing similar to that in the previously 
published work (29). We observed small but significant increases 
in adiposity in littermate control mice in response to GC that were 
not seen in the REVERBaKO animals. The increased adiposity in 
littermate controls was accompanied by a small but significant 
increase in fasting glucose, but there was no difference in glucose 
tolerance tests between genotypes. Previous work had shown a 
marked increase in insulin sensitivity in the REVERBaKO mice, 
and we also observed this, by comparison to littermate controls. 
However, in response to chronic GC dosing, there was a signifi-
cant loss of insulin sensitivity, but only in the REVERBaKO ani-
mals. Taken together we saw only minor changes in carbohydrate 
metabolic response to GC contingent on REVERBa expression, 
with loss of GC induction of adiposity in the REVERBaKO mice; 
and analysis of carbohydrate metabolic gene responses showed a 
number of changes but no consistent pattern (Supplemental Table 
6). Analysis of lipid metabolism in the REVERBaKO mice showed 
minimal effects on serum triglycerides, but we saw striking pro-
tection from hepatic steatosis, which is typically a consequence of 
supraphysiological GC exposure, in the REVERBaKO mice. The 
absence of changes in serum lipid profile suggests a mechanism 
of action localized to the liver, with likely involvement of lipid 
synthetic genes (Supplemental Table 5).
The discovery that REVERBa serves as an additional mech-
anism linking the core circadian clockwork to GC action raised 
the question of mechanism. In our first studies, we saw major 
circadian control of gene expression in the liver (28). The greatest 
differences between genotypes were seen in the transactivated 
genes, with a loss of daytime acetylation. There was little change 
in nighttime acetylation seen in the REVERBaKO animals, perhaps 
as nighttime is the nadir of REVERBa expression. This change is 
concordant with the observed changes in target gene response 
between genotypes, with WT mice having far more transactivated 
genes by day. This further supports a chromatin remodeling mech-
anism as the explanation for time-of-day and genotype differences 
in GC response, and again implicates REVERBa as a critical medi-
ator of the time-of-day effect.
HNF4A and HNF6 are required for time-of-day regulation of GR 
action in the liver. As 2 HNF transcription factors emerged as can-
didate mediators of the GR/REVERBa crosstalk in the liver, we 
sought direct evidence for their role in conferring time-of-day reg-
ulation to GR action. Initially we focused on HNF4A, using a liver- 
specific Hnf4a-KO mouse (Hnf4afl/flAlbCre) and Cre-negative lit-
termates as control (32). The experimental design was the same as 
above, with GC administration timed to ZT6 or ZT18, followed by 
liver harvest 2 hours later and mRNA analysis. As older Hnf4afl/fl 
AlbCre mice develop hepatic abnormalities, we used young mice 
(8 weeks of age), which showed no overt signs of illness, no dif-
ferences in weight gain, and no gross hepatic abnormalities (33). 
We targeted 19 genes from the list of GR and REVERBa co-bound 
genes with a time-of-day difference in gene expression. Of these, 9 
(47%) showed a genotype effect (Figure 9A, Supplemental Figure 
12A, and Supplemental Table 12). We found no effect on GR gene 
expression or on Reverba expression (Figure 9A). We observed 
both gain and loss of temporal GR regulation (Figure 9A).
We also investigated HNF6, the other potential regulator 
identified in Figure 8. Here we used an AAV6-delivered shRNA 
approach. C57BL/6J mice were tail vein–injected with the AAV 
carrying either the targeting shRNA or a control sequence, and 
3 weeks later the mice were treated with timed GC administra-
tion (ZT6 or ZT18), and mRNA analysis was conducted 2 hours 
later. We found that HNF6 knockdown was incomplete, with 
some variability between mice (Supplemental Figure 13, A and 
B), and therefore confined our analysis to livers where HNF6 
protein expression was lower than the median level seen in the 
control mice (Supplemental Figure 13, A and B). Reduction of 
HNF6 expression also affected time-of-day GR action, but had 
no significant effect on either GR or Reverba/b gene expression 
(Supplemental Figure 12B). Unsurprisingly, we identified differ-
ent genes affected by reduction in HNF6 compared with those 
seen in the Hnf4a-KO livers, as the 2 HNFs have different target 
sequence binding specificity (Figure 9B). We therefore define a 
complex GR regulatory network in liver where REVERBa carries 
critical timing information and the HNFs work cooperatively to 
confer liver specificity of effect.
Discussion
Therapeutic use of GC in humans remains common, but is plagued 
by major off-target effects. GC use is a major risk factor for hepatos-
teatosis, a state leading to disruption of liver function, with result-
ing inflammation, fibrosis, and organ failure. There is renewed 
interest in timing of GC therapy, with nighttime release of prednis-
olone offering a small additional therapeutic effect (25). Our data 
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Figure 8. Rhythmicity of GC sensitivity in liver is determined by REVERBa and HNF transcription factors. (A) Base mean expression versus log2 fold 
change plots for GC-regulated genes in day and night show direction of gene regulation. (B) Summary of top-ranked motifs (by coverage [%], defined as 
fraction of observed/expected proportions taken from HOMER output) under all GR peaks or GR/REVERBa co-bound peaks (interpeak distance, <120 bp). 
(C) Overlay of GC-regulated genes with GR/REVERBa/HNF ChIP-Seq in the day and night. (D) ChIP-PCR for GR-REVERBa target genes in liver associated 
with carbohydrate (Tat) and lipid ontology (Lpin1) (n = 3–4); graphs show individual values and median. (E) C57BL/6 (WT) and REVERBaKO mice (male 
and female) were given 1 mg/kg i.p. dex or vehicle at ZT6 or ZT18 for 1 hour; livers were removed and fixed, and chromatin was immunoprecipitated for 
H3K27Ac (n = 2). Fold change in H3K27Ac coverage from prior to the transcription start site of genes upregulated or downregulated specifically during the 
day (top), and genes upregulated or downregulated specifically during the night (bottom) in WT and REVERBaKO mice identified from RNA-Seq in Figure 
3. Statistical analysis via Mann-Whitney U test (ChIP-PCR), *P < 0.05.
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Cell lines. Mycoplasma-free HEK293 cells were purchased from 
ATCC and maintained in DMEM (4,500 mg glucose/l, 110 mg sodium 
pyruvate/l, and l-glutamine, Sigma-Aldrich) with 10% v/v heat-inac-
tivated FBS (Invitrogen) in a humidified atmosphere of 5% carbon 
dioxide at 37°C.
Primary bone marrow–derived macrophages were purified and 
cultured in growth media (DMEM containing 4,500 mg/l glucose, 110 
mg/l sodium pyruvate, l-glutamine, and 10% heat-inactivated bovine 
serum) supplemented with 0.1 mg/ml M-CSF in a humidified atmo-
sphere of 5% carbon dioxide at 37°C.
Animals. Experimentation was performed on mouse strains 
C57BL/6J (WT) from Harlan Blackthorn and global REVERBaKO mice 
and littermate controls imported from GlaxoSmithKline. There, the 
REVERBaKO mice were re-derived (from the original colony held by 
Ueli Schibler, Geneva, Switzerland) using in vitro fertilization proce-
dures, with resulting heterozygous REVERBaKO animals subsequently 
backcrossed to a C57BL/6J background to over 98%, as confirmed by 
Marker-Assisted Accelerated Backcrossing (MAXBax, Charles River). 
Homozygous REVERBaKO and WT littermate controls were gener-
ated through heterozygous × heterozygous matings. Animals housed 
at GlaxoSmithKline were multiply housed in autoclaved Tecniplast 
GM500 IVC cages containing IPS Lignocel BK8/15 bedding with Date-
sand Paper Shavings nesting material, within a Tecniplast Smart Flow 
ventilation system. Animals were maintained at an ambient tempera-
ture of 20.5ºC to 23.5ºC and relative humidity of 39% to 61%, main-
tained on a 12-hour light/12-hour dark cycle, with free access to food 
(LabDiet Irradiated 5LF2 Maintenance Diet) and water. All mice (8–22 
weeks old, male and female) were acclimatized in the biological ser-
vices facility for 1 week before any procedures were undertaken. All 
procedures were performed in compliance with the Animals (Scientific 
Procedures) Act of 1986. While housed in Manchester, mice had free 
access to food (unless otherwise stated) and water and were multiply 
housed in a 12-hour light/12-hour dark cycle.
Hnf4afl/fl and Hnf4aAlbCre mouse lines were described previously 
(32). Six- to 8-week-old male mice on a mixed SvJ129 and FVB back-
ground were used. Mice were housed in light- and temperature-con-
trolled rooms and provided water and pelleted chow ad libitum.
HNF6 shRNA targeting. Twelve-week-old male C57BL/6J mice 
(Envigo) were used for HNF6-knockdown experiments. Animals were 
randomly allocated to treatment groups and coded. Samples were pro-
cessed and decoded after analysis to limit any investigator bias. A cus-
tom adeno-associated viral vector against Hnf6 (Onecut1) was gener-
ated. Mice were treated with 2E11 particles AAV6-EF1a-shmirOnecut1 
(n = 20) or AAV6-EF1a-NTshmir (n = 16) (generated by Sirion Biotech) 
by tail vein injection. After 3 weeks, mice were used for experiments.
Acute GC treatment. Mice were treated at ZT6 (6 hours after lights 
on, 1:30 pm) or at ZT18 (6 hours after lights off, 1:30 am) with dex (1 
mg/kg i.p.) or vehicle (1 mg/kg methylcyclodextrin i.p., Hnf4afl/fl and 
Hnf4aAlbCre mice received saline vehicle) for either 2 or 4 hours before 
sacrifice by cervical dislocation.
Chronic GC treatment. Mice (n = 8) were treated at ZT6 (6 hours 
after lights on) with dex (1 mg/kg i.p.) or vehicle (saline i.p.) every 48 
hours for 8 weeks before sacrifice by cervical dislocation. Two mice 
(one REVERBaKO vehicle, one REVERBaKO dex) were sacrificed prior 
to the end of the study for poor health. With the exception of hepatic 
triglyceride analysis, which is an early and robust GC response, all other 
samples from these animals were excluded from subsequent analysis.
differences between metabolic (liver) and nonmetabolic (lung) 
tissue. In addition, we observed no impact of REVERBa loss on 
thymic atrophy or on liver inflammatory gene regulation by GC, 
suggesting very strong target gene and cell type specificity effects 
of the crosstalk. These observations prompted us to investigate 
the DNA sequences underlying peaks of GR/REVERBa co-bind-
ing in the liver. We saw a strong enrichment for the hepatic lin-
eage-determining factors HNF4A and HNF6, which was inter-
esting, as these factors had previously been found independently 
to be required for both GR and REVERBa recruitment to specific 
sites in the hepatocyte genome. Further analysis of the chromatin 
modification pattern at the co-bound sites uncovered time-of-day 
variation in the very histone mark most strongly associated with 
productive REVERBa recruitment, H3K9Ac. The coalignment of 
binding sequences for REVERBa, GR, and the sites of time-of-day 
variation in H3K9Ac is quite striking on genes shown to have time- 
dependent variation in GC response, including Dgat2 and Lpin2. 
Therefore, we propose the existence of composite elements with-
in energy metabolic genes, which become accessible in the liver 
under the influence of the HNFs, which serve as loci for crosstalk 
between GR and REVERBa. A prediction from this model is that 
recruitment of GR to its cognate enhancer elements in relation to 
these genes will be regulated by time of day, and also REVERBa 
status. Indeed, we did observe loss of GR recruitment to these 
sites at night in WT animals, when the GC response of these genes 
is lost, and a similar loss of GR recruitment in the REVERBaKO 
mice. Looking across all the GC-regulated genes, we saw a marked 
REVERBa effect, mainly on the H3K27 acetylation status of day-
time GC-transactivated genes, which again fits with an underlying 
chromatin remodeling mechanism. Furthermore, using either liv-
er-specific KO of Hnf4a or shRNA-mediated knockdown of Hnf6, 
we demonstrated that these nuclear receptors are required for 
gene-specific control of time-of-day GR responses at REVERBa- 
dependent sites.
Close cross-coupling between cellular clock machinery and 
GR is supported by overlapping roles in regulating (a) energy 
metabolism and immunity, (b) protein interactions between CRY 
and GR to affect carbohydrate metabolism, (c) and the potent 
clock-entraining activity of the GR, which transactivates Per2 
(22). To these we now add the physical interaction and functional 
cooperativity between GR and REVERBa. There has been limited 
application of timing information in GC therapy, with nighttime 
release of prednisolone offering a small additional therapeutic 
effect (25). Our studies suggest that timed administration of GC 
can be a powerful tool in targeting specific physiological programs, 
for example, by avoiding the detrimental metabolic actions of GCs 
in the liver but maintaining antiinflammatory activity.
Methods
Materials. Anti–mouse GR antibody (catalog sc-1004) was purchased 
from Santa Cruz Biotechnology Inc.; anti–human GR antibody (cat-
alog 24050-1-AP) was purchased from Proteintech. GSK6F05 anti- 
REVERBa was generated in collaboration with GlaxoSmithKline (34). 
ONECUT1 (HNF6) rabbit pAb (catalog 25137-1-AP, lot 00021988) and 
ACTB mouse mAb (catalog 0008-1, lot 0001084) were purchased 
from Proteintech. Dex, methyl-cyclodextrin, dextrose, and standard 
chemicals were purchased from Sigma-Aldrich.
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Figure 9. Hnf4a and Hnf6 selectively regulate rhythmic GC action. (A) Hnf4aAlbCre and Hnf4afl/fl controls were treated with 1 mg/kg dex at ZT6 or 
ZT18 and culled 2 hours later. Livers were harvested, and RNA was analyzed via NanoString (n = 5–7 per group). (B) C57BL/6J mice were injected 
with shRNA against Hnf6. Mice were treated with 1 mg/kg dex at ZT6 or ZT18 and culled 2 hours later. Livers were harvested, and RNA was ana-
lyzed via NanoString (n = 3–7 per group). Genotype × treatment × time interactions were analyzed by limma; *q < 0.05, **q < 0.01, ***q < 0.001, 
****q < 0.0001. Data shown for individual mice and median.
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Mitochondrial genome quantification. Livers and lungs were 
homogenized, DNA was extracted using TRIzol (Invitrogen), and 
relative mitochondrial DNA (ND1) was quantified using qRT-PCR 
(Applied Biosystems). Expression levels were calculated using the 
δδCT method, normalizing to the nuclear genome (GAPDH). Primer 
sequences are described in Supplemental Table 7 (n = 10 for all lung 
treatment groups; n = 10 vehicle liver ZT6, n = 9 dex liver ZT6 and 
vehicle liver ZT18, and n = 7 dex liver ZT18).
Nanostring RNA analysis. Total RNA was extracted from flash-fro-
zen liver tissue (ReliaPrep RNA Tissue Miniprep System, Promega). 
Gene expression in 100 ng RNA was quantified using NanoString 
nCounter technology, using a custom codeset of probes (Supplemen-
tal Tables 8–12). mRNA counts were normalized to the housekeep-
ing genes Actb and B2m using nSolver software (NanoString). Gene 
expression analysis was performed on log2-transformed normalized 
counts using the Bioconductor package limma (39), with an FDR (Ben-
jamini-Hochberg) threshold of 0.05.
Transcription factor ChIP-Seq analysis. GR ChIP-Seq data from GEO 
GSE46047 (9) were downloaded, and FastQ files were mapped to the 
mm10 genome using Bowtie1 (40) with default options except the “−
m1” option, keeping only uniquely mapped reads. Peaks were called 
using MACS 2.1.0 (41) with default parameters, except the “–nolamb-
da” option. To associate identified peaks to mm10 annotated genes, 
HOMER (42) (annotatePeaks.pl) was used, with default options.
Co-binding analysis. ChIP-Seq datasets (BED files for mm9 assem-
bly) for GR (GR 6:00 am/6:00 pm; GSE59764 (12) and core clock 
transcription factors (GSE3986, ref. 28, and GSE34020, ref. 16) were 
downloaded from GEO and lifted to the mm10 assembly using the 
UCSC liftOver tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver). 
For each of the clock transcription factors, histograms were drawn for 
summit-to-summit distances between each GR peak and its nearest 
clock transcription factor peak, as described previously (43).
Motif analysis. Regions from the GR BED file with a REVERBa peak 
within 120 bp were extracted, and HOMER (findMotifsGenome.pl) 
was used to find enriched de novo and known motifs in these co-bound 
regions, as well as locations of top motifs. Motifs were built using the 
options “-len 8,12,15,” and “-size 200,” while when finding locations of 
the selected motifs, the option “-size given” was used. Output motifs were 
ranked based on %Ratio (observed/expected frequencies). Duplicate 
motifs, or motifs with %Ratio <1.5 or total coverage <5%, were removed.
ChIP. ChIP was performed using the ChIP-IT High Sensitivity 
kit (Active Motif) according to manufacturer’s instructions. A Tis-
sueRuptor (QIAGEN) was used for 45 seconds at maximum speed 
to disrupt liver tissue, followed by Dounce homogenizing for 70 
strokes to release cell nuclei. Nuclear sonication was conducted 
with an EpiShear Probe Sonicator (Active Motif, 3.5-mm probe) for 
8 rounds of 2 minutes per sample, at 37% amplitude. 15 μg sheared 
chromatin was incubated with anti-H3K27Ac antibody (Active 
Motif, lot 31814008) or an anti-GR antibody cocktail (Proteintech 
24050-1-A, lot 00044414, and Cell Signaling Technology, D8H2, 
lot 2). For GR ChIP, 30 ng spike-in Drosophila melanogaster chroma-
tin (Active Motif) plus an antibody to the Drosophila-specific histone 
variant H2Av (Active Motif Spike-in Antibody 61686; lot 34216004) 
(44) were include in the IP reaction. Antibody was pulled down with 
magnetic protein G agarose microspheres (ReSyn Biosciences). 
After elution and de-crosslinking, ChIP DNA was purified, as per 
the kit instructions.
Glucose tolerance tests. Mice were fasted overnight (12 hours) and 
injected at ZT6 with 2 g/kg dextrose. Blood glucose was measured 
over 3 hours (Aviva Accu-Chek). Glucose tolerance tests (GTTs) were 
performed prior to chronic treatment (week –1; WT n = 8 biological 
replicates, REVERBaKO n = 7 biological replicates).
Insulin tolerance tests. Mice were fasted for 4 hours and injected at 
ZT6 with 0.75 U/kg recombinant human insulin (Sigma-Aldrich, lot 
SLBM5131V). Blood glucose was measured over 90 minutes (Aviva 
Accu-Chek) (WT n = 8 biological replicates, REVERBaKO n = 7 bio-
logical replicates).
Body weight and adiposity. Mice were weighed every 48 hours 
between ZT3 and ZT5 and placed in an EchoMRI-900 (Echo Medical 
Systems) every 2 weeks between ZT6 and ZT9 for a total read time of 
between 140 and 160 seconds. An average of 3 readings were taken. Per-
cent body fat was calculated from values determined by the EchoMRI 
(WT n = 8 biological replicates, REVERBaKO n = 7 biological replicates).
Ex vivo LPS challenge. Bones from REVERBaKO mice and litter-
mate controls (males, aged 12–16 weeks) were collected and processed 
independently (n = 3). Primary cells were cultured in growth media 
supplemented with 0.1 mg/ml M-CSF for 7 days. On day 8, cell culture 
medium was replaced (without M-CSF), and cells were treated with 
vehicle or 100 nM dex for 1 hour and then 100 ng/ml LPS for a further 
4 hours. Cells were lysed and processed for qRT-PCR.
RNA-Seq. Lung and liver were lysed and total RNA prepared using the 
SV Total RNA Isolation System (Promega). Quality and integrity of total 
RNA samples were assessed by a 2100 Bioanalyzer or a 2200 TapeSta-
tion (Agilent Technologies) according to the manufacturer’s instructions.
RNA-Seq libraries were generated using the TruSeq Stranded 
mRNA assay (Illumina) according to the manufacturer’s protocol, then 
paired-end sequenced (101 + 101 cycles, plus indices) on an Illumina 
HiSeq 2500 instrument. Demultiplexing of the output data (allowing 
one mismatch) and BCL-to-FastQ conversion were performed with 
CASAVA 1.8.3. FastQ files containing paired-end reads were quali-
ty checked with the FastQC tool, followed by Trimmomatic (35) and 
filtered reads aligned to the GRCm38.71 (mm10) assembly of the 
mouse genome using TopHat 2.0.11 (36). Mapped reads to genes were 
counted, for Ensembl annotation GRCm38.71, using HTSeq-count 
(v0.5.4p5) (37), with default quality score and with options “strand-
ed=reverse” and “intersection_nonempty.”
DESeq2 (38) was used to perform normalization and pairwise 
comparisons. Differentially expressed (DE) genes were reported for q 
≤ 0.05 and fold change of 2 (Figure 1) or q ≤ 0.1 (Figure 3) and were 
taken forward for downstream analysis. The online bioinformatics 
tools webgestalt (http://www.webgestalt.org/) and Enrichr (http://
amp.pharm.mssm.edu/Enrichr/) were used for enrichment analysis 
of the DE genes. Sequencing datasets were deposited in Array Express 
under the accession numbers E-MTAB-7020, E-MTAB-7017, and 
E-MTAB-6994.
qRT-PCR. Lung, liver, and macrophages were lysed, and total RNA 
was prepared using the SV Total RNA Isolation System. Total RNA was 
reverse transcribed to cDNA using a High Capacity RNA-to-cDNA Kit 
(Applied Biosystems) and subjected to qRT-PCR using SYBR Green 
(KAPA Biosystems) detection in a StepOnePlus Real-Time PCR System 
(Applied Biosystems). All samples were analyzed in duplicate. Expres-
sion levels were calculated using the δδCT method, normalizing to 
β- actin control (lung and liver, n = 4 biological replicates; macrophages, 
n = 3 biological replicates).
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Immunoprecipitation. HEK293 cells were transfected with 1 μg 
halo-tagged REVERBa and/or 1 μg halo-tagged GR using polyethylen-
imine (PEI) (3:1 v/w ratio) and left overnight. Cells were transferred to 
media containing charcoal-stripped FBS (Invitrogen) 4 hours before 
treatment with dex (100 nM) or DMSO for 1 hour, then lysed (150 mM 
NaCl, 20 mM Tris-HCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 
10 mM N-ethylmaleimide [NEM], PhosSTOP, cOmplete EDTA-free 
protease inhibitor cocktail [MilliporeSigma]) on ice, and cell debris 
was cleared by centrifugation. 1 μg anti-REVERBa antibody (mouse 
monoclonal GSK6F05, or 1 μg mouse IgG) or 1 μg anti GR antibody 
(rabbit polyclonal, Proteintech, or 1 μg rabbit IgG) was incubated with 
protein lysates for 1 hour, and antibody complexes were captured 
using magnetic beads (Surebeads protein G magnetic beads, Bio-Rad; 
MagReSyn Protein A, ReSyn Biosciences) for 45 minutes at 4°C. Beads 
were washed with lysis buffer, then boiled in SDS loading dye.
Immunoblotting. Livers were lysed (150 mM NaCl, 20 mM Tris-
HCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 mM NEM, 
PhosSTOP, cOmplete EDTA-free protease inhibitor cocktail) and pro-
tein quantified using Bradford Assay (Bio-Rad). Samples were elec-
trophoresed on Mini PROTEAN TGX Precast Gels 4-15% (Bio-Rad) 
and transferred to 0.2-μm Protran nitrocellulose membranes. Mem-
branes were blocked (5% skim milk powder in TBST, 50 mM Tris, 
150 mM NaCl, pH 7.6, 0.1% Tween-20) for 1 hour at room tempera-
ture and then incubated with mouse monoclonal GSK6F05 anti-RE-
VERBa, rabbit polyclonal anti-GR (Proteintech), mouse monoclonal 
anti-ACTB (Proteintech), or rabbit polyclonal anti-ONECUT1 (HNF6) 
(Proteintech) antibodies overnight at 4°C. Membranes were washed 
in TBST and secondary HRP-linked antibodies (GE Healthcare), or 
Dylight-680/800 secondary antibodies (Cell Signaling Technology) 
were incubated for 1 hour. After washes in TBST, immunoreactive 
bands were detected using SuperSignal West Dura (Thermo Fisher 
Scientific), and chemiluminescence was visualized on Kodak BioMax 
MR or XAR Film or LI-COR Odyssey CLx.
Corticosterone measurements. Blood was left to clot for 30 minutes 
and centrifuged for 10 minutes at 1,000 g, and serum was collected. 
Serum was diluted 1:40, and duplicate samples were run alongside a 
standard curve of corticosterone (range 32–27,000 pg/ml) according 
to the manufacturer’s instructions (Corticosterone ELISA kit, catalog 
ADI-900-097, Enzo).
Insulin measurements. Blood was left to clot for 30 minutes and 
centrifuged for 10 minutes at 1,000 g, and serum was collected. Serum 
was diluted 1:2, and samples were analyzed alongside standard a curve 
of insulin (range 37–150,000 pg/ml) according to the manufacturer’s 
instructions (MILLIPLEX MAP Mouse Bone Magnetic Bead Panel, 
catalog MBNMAG, Millipore) using the Bioplex 200 system (Bio-Rad) 
(WT n = 8, REVERBaKO n = 7 biological replicates).
Liver glycogen measurements. Liver homogenates (10 mg/100 μl) 
were boiled for 5 minutes and cleared by centrifugation at 13,000 g for 
10 minutes. Single measurements of 0.5 and 0.1 μl sample/well were 
run alongside a standard curve of glycogen (range 0.2–2 μg) according to 
the manufacturer’s instructions (Glycogen Assay Kit, catalog MAK016, 
Sigma-Aldrich) (WT n = 8, REVERBaKO n = 7 biological replicates).
Triglyceride and free fatty acid measurements. Liver homogenates 
(10 mg/100 μl) and serum were isolated. Undiluted serum samples 
and liver homogenates (diluted 1:2) were run in duplicate alongside a 
standard curve of glycerol (range 0.037–2.5 mg/ml, triglyceride assay) 
or palmitic acid (range 0.2–1 nmol, free fatty acid assay) according 
H3K27ac ChIP-Seq. 5–10 ng ChIP DNA was submitted to the Uni-
versity of Manchester Genomics Facility for library preparation and 
paired-end sequencing on the Illumina HiSeq 4000 platform. Reads 
were trimmed and aligned to the mm10 genome using Bowtie 2 (45). 
Reads were counted (in 100-bp windows) for the lists of dex up-/
downregulated genes (as identified from RNA-Seq in Figure 3) in both 
C57BL/6 (WT) and REVERBaKO mice using BEDTools (46). The sites 
are redefined as 2 kb either side of the TSS to make them symmetrical. 
Regions that overlap with ChIP-Seq blacklisted regions were filtered 
out. The data are presented as fold change compared with average 
read count in the 1 kb preceding the site. The values plotted are aver-
ages over the total number of sites.
GR ChIP-ddPCR. 2 μl ChIP DNA was added to each PCR reaction 
comprising QX200 ddPCR EvaGreen Supermix (Bio-Rad) and prim-
ers listed in Supplemental Table 7. To normalize ddPCR results, one 
spike-in value (as copies per microliter of the PCR reaction) was cho-
sen as the reference value. For each other sample, the reference spike-
in value was divided by that sample’s spike-in value, to create a nor-
malization factor. Values for the targets of interest (also as copies per 
microliter of the PCR reaction) were then multiplied by this normal-
ization factor, as per the manufacturer’s (Active Motif) instructions.
Histology. Lungs were immediately infused with 1 ml of 4% para-
formaldehyde then submerged in 4% paraformaldehyde overnight. 
Livers and visceral adipose were submerged in 4% paraformaldehyde 
overnight. Tissues were embedded into paraffin blocks and cut into 
5-μm sections (Leica RM2255 Microtome).
For antibody staining, sections were dewaxed using xylene, 
rehydrated through an alcohol series, then water and endogenous 
peroxidase quenched with 0.003% v/v H2O2. Samples were washed 
with PBS, antigen retrieved (10 mM citric acid, pH 6) for 20 minutes, 
and then washed again in PBS. After avidin/biotin blocking (Vector 
Laboratories), sections were incubated with primary antibody (GR 
M20, Santa Cruz Biotechnology Inc., 1:200 in PBS/0.1% v/v Triton 
X-100/3% goat serum) overnight at 4°C. Sections were washed with 
PBS, incubated with biotinylated anti-rabbit (Vector Laboratories, 
1:800 in PBS/0.1% v/v Triton X-100) for 2 hours at 4°C, washed again 
with PBS, and then incubated with streptavidin-conjugated horserad-
ish peroxidase (1:200 in PBS) for 1 hour at 4°C. After final washes in 
PBS, color detection was performed using DAB (Vector Laboratories), 
and nuclei were counterstained with toluidine blue. Sections were 
then dehydrated through an alcohol series, then xylene, and mounted 
using Entallan (Merck).
For the H&E staining, paraffin-embedded adipose or liver 
sections were rehydrated through an alcohol series and brought to 
distilled water. Nuclei were stained with hematoxylin (2 minutes); 
rinsed in tap water; stained with eosin (2 minutes); rinsed with 
tap water; dehydrated through an alcohol series, then xylene; and 
mounted using Entallan.
All images were acquired on an Axio Imager.A1 (Zeiss) microscope 
using either a ×10 or ×20 Zeiss EC Plan-Neofluar objective, using 
AxioCam MRc (Zeiss). Raw images were visualized using AxioVision 
Rel. 4.7 (Zeiss), processed, and quantified using the NIH ImageJ Adi-
pocytes Tool (http://dev.mri.cnrs.fr/projects/imagej- macros/wiki/
Adipocytes_Tool).
Metabolic profiling. Quantification of ATP, ADP, AMP, NAD, 
NADP, and NADPH from flash-frozen liver was performed by the 
Metabolomics Innovation Centre (TMIC) at the University of Alberta.
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phages. DRS and DAD generated the REVERBa mAb. ASIL, DAB, 
MR, LCM, and DWR supervised the project. GC, DAB, MR, LCM, 
and DWR wrote the manuscript. GC and LCM prepared the fig-
ures. All authors edited the manuscript.
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